134 related articles for article (PubMed ID: 19365283)
21. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
22. Use of statins and blood pressure.
King DE; Mainous AG; Egan BM; Player M; Geesey ME
Am J Hypertens; 2007 Sep; 20(9):937-41. PubMed ID: 17765132
[TBL] [Abstract][Full Text] [Related]
23. Alcohol-induced macrocytosis and blood pressure.
Seppä K; Sillanaukee P; Pitkäjärvi T; Saarni M
Alcohol Alcohol; 1992 May; 27(3):287-92. PubMed ID: 1360215
[TBL] [Abstract][Full Text] [Related]
24. A blunted decrease in nocturnal blood pressure is independently associated with increased aortic stiffness in patients with resistant hypertension.
Castelpoggi CH; Pereira VS; Fiszman R; Cardoso CR; Muxfeldt ES; Salles GF
Hypertens Res; 2009 Jul; 32(7):591-6. PubMed ID: 19444279
[TBL] [Abstract][Full Text] [Related]
25. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal.
Zanchetti A; Grassi G; Mancia G
J Hypertens; 2009 May; 27(5):923-34. PubMed ID: 19381107
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive, antioxidant, antidyslipidemic and endothelial modulating activities of a polyherbal formulation (POL-10).
Aziz N; Mehmood MH; Mandukhal SR; Bashir S; Raoof S; Gilani AH
Vascul Pharmacol; 2009; 50(1-2):57-64. PubMed ID: 18940267
[TBL] [Abstract][Full Text] [Related]
27. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
[TBL] [Abstract][Full Text] [Related]
28. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
[TBL] [Abstract][Full Text] [Related]
30. Central and Brachial Blood Pressures, Statins, and Low-Density Lipoprotein Cholesterol: A Mediation Analysis.
Lamarche F; Agharazii M; Nadeau-Fredette AC; Madore F; Goupil R
Hypertension; 2018 Mar; 71(3):415-421. PubMed ID: 29295849
[TBL] [Abstract][Full Text] [Related]
31. Cellular phone and Internet-based individual intervention on blood pressure and obesity in obese patients with hypertension.
Park MJ; Kim HS; Kim KS
Int J Med Inform; 2009 Oct; 78(10):704-10. PubMed ID: 19643661
[TBL] [Abstract][Full Text] [Related]
32. The antihypertensive actions of statins: modulation by salt intake.
Juncos LI; Juncos LA; García NH
Am J Hypertens; 2012 Nov; 25(11):1140-8. PubMed ID: 22833031
[TBL] [Abstract][Full Text] [Related]
33. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions.
Yamashita S; Tsubakio-Yamamoto K; Ohama T; Nakagawa-Toyama Y; Nishida M
J Atheroscler Thromb; 2010 May; 17(5):436-51. PubMed ID: 20513953
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients.
Tsouchnikas I; Dounousi E; Papakonstantinou S; Ioannou K; Kelesidis A; Kotzadamis N; Xanthopoulou K; Tsakiris D
Nephrology (Carlton); 2009 Sep; 14(6):560-4. PubMed ID: 19422526
[TBL] [Abstract][Full Text] [Related]
37. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
Pede S; Lombardo M
Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
[TBL] [Abstract][Full Text] [Related]
38. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
39. Pulse wave velocity and coronary risk stratification.
Mendonça MI; Reis RP; Sousa AC; Gomes S; Faria P; Pereira A; Silva B; Serrão M; Santos N; Sousa FS; Silva JA; Sousa J; Ornelas I; Freitas S; Cardoso A; Araújo JJ
Rev Port Cardiol; 2009 Feb; 28(2):155-71. PubMed ID: 19438151
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
Wiviott SD; Mohanavelu S; Raichlen JS; Cain VA; Nissen SE; Libby P
Am J Cardiol; 2009 Jul; 104(1):29-35. PubMed ID: 19576317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
